237 related articles for article (PubMed ID: 28082032)
1. Recommendations for the use of parenteral methotrexate in rheumatic diseases.
Tornero Molina J; Calvo Alen J; Ballina J; Belmonte MÁ; Blanco FJ; Caracuel MÁ; Carbonell J; Corominas H; Chamizo E; Hidalgo C; Ivorra JR; Marenco JL; Moreno Muelas JV; Muñoz-Fernández S; Nolla JM; Pérez T; Sanmarti R; Trenor P; Urrego C; Vidal J; Rosas Gomez de Salazar J
Reumatol Clin (Engl Ed); 2018; 14(3):142-149. PubMed ID: 28082032
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for the use of methotrexate in psoriatic arthritis.
Cañete JD; Ariza-Ariza R; Bustabad S; Delgado C; Fernández-Carballido C; García Llorente JF; Loza E; Montilla C; Naranjo A; Pinto JA; Queiro R; Ramírez J; Tornero-Molina J
Reumatol Clin (Engl Ed); 2018; 14(4):183-190. PubMed ID: 29050840
[TBL] [Abstract][Full Text] [Related]
3. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
Reumatol Clin (Engl Ed); 2022 Jan; 18(1):33-41. PubMed ID: 35090610
[TBL] [Abstract][Full Text] [Related]
4. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis.
Tornero Molina J; Balsa Criado A; Blanco García F; Blanco Alonso R; Bustabad S; Calvo Alen J; Corominas H; Fernández Nebro A; Román Ivorra JA; Sanmartí R
Reumatol Clin (Engl Ed); 2020; 16(4):272-281. PubMed ID: 30098882
[TBL] [Abstract][Full Text] [Related]
5. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.
Visser K; Katchamart W; Loza E; Martinez-Lopez JA; Salliot C; Trudeau J; Bombardier C; Carmona L; van der Heijde D; Bijlsma JW; Boumpas DT; Canhao H; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Murphy G; Østergaard M; Pereira IA; Ramos-Remus C; Valentini G; Zochling J; Dougados M
Ann Rheum Dis; 2009 Jul; 68(7):1086-93. PubMed ID: 19033291
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
[TBL] [Abstract][Full Text] [Related]
7. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
Reumatol Clin (Engl Ed); 2020 Oct; ():. PubMed ID: 33041228
[TBL] [Abstract][Full Text] [Related]
8. [Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"].
De Leonardis F; Alivernini S; Bonacci E; Buono AM; Bombardieri S; Ferraccioli GF; Montecucco C; Sinigaglia L; Trotta F; Valentini G
Reumatismo; 2010; 62(1):34-45. PubMed ID: 20390116
[TBL] [Abstract][Full Text] [Related]
9. [Portuguese recommendations for the use of methotrexate in the treatment of rheumatoid arthritis].
Canhão H; Santos MJ; Costa L; Bogas M; Mourão AF; Machado P; Fonseca JE; Silva JA;
Acta Reumatol Port; 2009; 34(1):78-95. PubMed ID: 19377402
[TBL] [Abstract][Full Text] [Related]
10. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
11. Use of parenteral methotrexate in rheumatic diseases: A systematic review.
Otón T; Carmona L; Loza E; Rosario MP; Andreu JL
Reumatol Clin (Engl Ed); 2022 Apr; 18(4):207-226. PubMed ID: 35443927
[TBL] [Abstract][Full Text] [Related]
12. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
Bianchi G; Caporali R; Todoerti M; Mattana P
Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
[TBL] [Abstract][Full Text] [Related]
14. Optimal administration and dosage of methotrexate.
Braun J
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S46-51. PubMed ID: 21044433
[TBL] [Abstract][Full Text] [Related]
15. Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
Huang RY; Pan HD; Wu JQ; Zhou H; Li ZG; Qiu P; Zhou YY; Chen XM; Xie ZX; Xiao Y; Huang QC; Liu L
Phytomedicine; 2019 Apr; 57():403-410. PubMed ID: 30851515
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
17. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis.
Katchamart W; Bourré-Tessier J; Donka T; Drouin J; Rohekar G; Bykerk VP; Haraoui B; Leclerq S; Mosher DP; Pope JE; Shojania K; Thomson J; Thorne JC; Bombardier C;
J Rheumatol; 2010 Jul; 37(7):1422-30. PubMed ID: 20516029
[TBL] [Abstract][Full Text] [Related]
18. Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update.
Duarte AC; Santos-Faria D; Gonçalves MJ; Sepriano A; Mourão AF; Duarte C; Neves JS; Águeda AF; Ribeiro PA; Daniel A; Neto A; Cordeiro A; Rodrigues A; Barcelos A; Silva C; Ponte C; Vieira-Sousa E; Teixeira F; Oliveira-Ramos F; Araújo F; Barcelos F; Canhão H; Santos H; Ramos J; Polido-Pereira J; Tavares-Costa J; Melo Gomes JA; Cunha-Miranda L; Costa L; Cerqueira M; Cruz M; Santos MJ; Bernardes M; Oliveira P; Abreu P; Figueira R; Barros R; Falcão S; Pinto P; Pimenta S; Capela S; Teixeira V; Fonseca JE
Acta Reumatol Port; 2017; 42(2):127-140. PubMed ID: 28535545
[TBL] [Abstract][Full Text] [Related]
19. Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review.
Colebatch AN; Marks JL; van der Heijde DM; Edwards CJ
J Rheumatol Suppl; 2012 Sep; 90():62-73. PubMed ID: 22942332
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis.
Todoerti M; Maglione W; Bernero E; Bortoluzzi A; Colaci M; Galuppi E; Paolino S; Talarico R; Cutolo M; Ferri C; Trotta F; Bombardieri S; Montecucco CM; Sinigaglia L
Reumatismo; 2013 Dec; 65(5):207-18. PubMed ID: 24399184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
